Ledyard National Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Ledyard National Bank’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-200	Closed	-$14K	–	605
2016 Q3	$14K	Hold	200	–	–	﹤0.01%	450
2016 Q2	$11K	Hold	200	–	–	﹤0.01%	454
2016 Q1	$13K	Hold	200	–	–	﹤0.01%	488
2015 Q4	$19K	Hold	200	–	–	﹤0.01%	434
2015 Q3	$16K	Hold	200	–	–	﹤0.01%	439
2015 Q2	$24K	Buy	+200	New	+$23.9K	﹤0.01%	392

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SPC

Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ledyard National Bank's ALNY Position: Q4 2016 in Review

Ledyard National Bank sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2016, closing a stake of 200 shares — an estimated $14K sold.

Ledyard National Bank first reported a position in ALNY in Q2 2015 and held it in 6 quarters. The position peaked at $24K in Q2 2015. 211 funds tracked by Wall St. Rank hold ALNY as of Q4 2016.

Ledyard National Bank reported no remaining Alnylam Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Ledyard National Bank sold 200 Alnylam Pharmaceuticals shares in Q4 2016, an estimated $14K.
Ledyard National Bank first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Ledyard National Bank's Alnylam Pharmaceuticals position peaked at $24K in Q2 2015.
211 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2016.

Based on Ledyard National Bank's 13F filing for Q4 2016, filed 2 Feb 2017.